{"IGPH.SW": {"short_name": "IGEA Pharma N", "long_name": "IGEA Pharma N.V.", "summary": "IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States. The company offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. It also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. The company also engages in laboratory analysis. IGEA Pharma N.V. was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.", "currency": "CHF", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "EBS", "market": "ch_market", "country": "Netherlands", "city": "Hoofddorp"}, "PHG": {"short_name": "Koninklijke Philips N.V. NY Reg", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "NYQ", "market": "us_market", "country": "Netherlands", "city": "Amsterdam"}, "PHIA.AS": {"short_name": "PHILIPS KON", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "AMS", "market": "nl_market", "country": "Netherlands", "city": "Amsterdam"}, "PHIA.F": {"short_name": "KONINKL. PHILIPS ADR -,20", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "FRA", "market": "dr_market", "country": "Netherlands", "city": "Amsterdam"}, "PHIA.MI": {"short_name": "PHILIPS", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "MIL", "market": "it_market", "country": "Netherlands", "city": "Amsterdam"}, "PHIA.VI": {"short_name": "PHILIPS NV", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "VIE", "market": "at_market", "country": "Netherlands", "city": "Amsterdam"}, "QGEN": {"short_name": "Qiagen N.V.", "long_name": "QIAGEN N.V.", "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "NYQ", "market": "us_market", "country": "Netherlands", "city": "Venlo"}, "QGEN.VI": {"short_name": "QIAGEN NV", "long_name": "QIAGEN N.V.", "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "VIE", "market": "at_market", "country": "Netherlands", "city": "Venlo"}, "QIA.DE": {"short_name": "QIAGEN NV  EO -,01", "long_name": "QIAGEN N.V.", "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "GER", "market": "de_market", "country": "Netherlands", "city": "Venlo"}, "QIA.F": {"short_name": "QIAGEN NV  EO -,01", "long_name": "QIAGEN N.V.", "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "FRA", "market": "dr_market", "country": "Netherlands", "city": "Venlo"}, "RYLPF": {"short_name": "KONINKLIJKE PHILIPS NV", "long_name": "Koninklijke Philips N.V.", "summary": "Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, and diagnostic X-ray, as well as integrated clinical solutions; interventional X-ray systems, including cardiovascular, radiology and surgery, and interventional imaging and therapy devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation solutions; data, analytics, and actionable workflow products; and connected care informatics solutions. In addition, it provides power toothbrushes; infant feeding and digital parental solutions; male grooming and beauty products; and kitchen appliances, home care, garment care, and coffee products. Further, the company offers digital frameworks that connect consumers, patients, healthcare providers, payers, and partners in a cloud-based connected health ecosystem of solutions, products, systems, services, and devices. It has a strategic collaboration with BioIntelliSense to integrate BioSticker medical device into the company's remote patient monitoring offering to help monitor at-risk patients from the hospital into the home; a collaboration with Singapore General Hospital to establish the digital and computational pathology center of excellence; and partnership with InSightec. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "PNK", "market": "us_market", "country": "Netherlands", "city": "Amsterdam"}}